This is a working overview of pentapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-04. Anything still debated is marked as such rather than presented as settled.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
Healthcare centres, including clinics, doctor's offices, urgent care centers and ambulatory surgery centers, serve as first point of contact with a health professional and provide outpatient medical, nursing, dental, and other types of care services.
A sub-library can be paired with a complementary oligonucleotide and used as a DNA encoded library displaying a single covalently linked compound for affinity-based selection experiments. A sub-library can be paired with an oligonucleotide displaying a known binder to the target, thus enabling affinity maturation strategies. Two individual sublibraries can be assembled combinatorially and used for the de novo identification of bidentate binding molecules. Three different sublibraries can be assembled to form a combinatorial triplex library. Preferential binders isolated from an affinity-based selection can be PCR-amplified and decoded on complementary oligonucleotide microarrays or by concatenation of the codes, subcloning and sequencing. The individual building blocks can eventually be conjugated using suitable linkers to yield a drug-like high-affinity compound. The characteristics of the linker (e.g. length, flexibility, geometry, chemical nature and solubility) influence the binding affinity and the chemical properties of the resulting binder.(Fig.3) Bio-panning experiments on HSA of a 600-member ESAC library allowed the isolation of the 4-(p-iodophenyl)butanoic moiety. The compound represents the core structure of a series of portable albumin binding molecules and of Albufluor a recently developed fluorescein angiographic contrast agent currently under clinical evaluation.
Unlike gelatine, gulaman sets at room temperature and is uniquely thermo-reversible. If melted at higher temperatures, it can revert to its original shape once cooled down. Carrageenan jelly also sets more firmly than agar and lacks agar's occasionally unpleasant smell during cooking. The use of carrageenan as a gelatine substitute has spread to other parts of the world, particularly in cuisines with dietary restrictions against gelatine, like kosher and halal cooking. It has also been used in prepackaged Jello shots to make them shelf stable at room temperatures. Konjac is a gelling agent used in many Asian foods, including the popular konnyaku fruit jelly candies.
The epithelium of the ectocervix (the portion of the uterine cervix extending into the vagina) is an extension of, and shares a border with, the vaginal epithelium. The vaginal epithelium is made up of layers of cells, including the basal cells, the parabasal cells, the superficial squamous flat cells, and the intermediate cells. The basal layer of the epithelium is the most mitotically active and reproduces new cells. The superficial cells shed continuously and basal cells replace them. Estrogen induces the intermediate and superficial cells to fill with glycogen. Cells from the lower basal layer transition from active metabolic activity to death (apoptosis). In these mid-layers of the epithelia, the cells begin to lose their mitochondria and other organelles. The cells retain a usually high level of glycogen compared to other epithelial tissue in the body. Under the influence of maternal estrogen, the vagina of a newborn is lined by thick stratified squamous epithelium (or mucosa) for two to four weeks after birth. Between then to puberty, the epithelium remains thin with only a few layers of cuboidal cells without glycogen. The epithelium also has few rugae and is red in color before puberty. When puberty begins, the mucosa thickens and again becomes stratified squamous epithelium with glycogen-containing cells, under the influence of the girl's rising estrogen levels. Finally, the epithelium thins out from menopause onward and eventually ceases to contain glycogen, because of the lack of estrogen.
Collagen alpha-5(VI) chain also known as von Willebrand factor A domain-containing protein 4 is a protein that in humans is encoded by the COL6A5 gene. COL6A5 is a part of the Collagen VI gene family which produce collagen components for the Extracellular matrix of most connective tissues. In the human genome, part of the collagen VI family is located on chromosome 3q in order of COL6A4, COL6A5, COL6A6. Transcription of COL6A5 only occurs in skin, lung, testis, colon, and small intestine cells.
Sources: en.wikipedia.org
Flerovium is a synthetic chemical element; it has symbol Fl and atomic number 114. It is an extremely radioactive, superheavy element, named after the Flerov Laboratory of Nuclear Reactions of the Joint Institute for Nuclear Research in Dubna, Russia, where the element was discovered in 1999. The lab's name, in turn, honours Russian physicist Georgy Flyorov (Флёров in Cyrillic, hence the transliteration of "yo" to "e"). IUPAC adopted the name on 30 May 2012. The name and symbol had previously been proposed for element 102 (nobelium) but were not accepted by IUPAC at that time. It is a transactinide in the p-block of the periodic table. It is in period 7 and is the heaviest known member of the carbon group. Initial chemical studies in 2007–2008 indicated that flerovium was unexpectedly volatile for a group 14 element. More recent results show that flerovium's reaction with gold is similar to that of copernicium, showing it is very volatile and may even be gaseous at standard temperature and pressure. Nonetheless, it also seems to show some metallic properties, consistent with it being the heavier homologue of lead. Very little is known about flerovium, as it can only be produced one atom at a time, either through direct synthesis or through radioactive decay of even heavier elements, and all known isotopes are short-lived.
=== Anti-Drug Abuse Act === Spurred by the media craze over the war on drugs the House of Representatives allocated $2 billion in new funding to the federal anti-drug fight in 1986. The House also authorized the use of the military in narcotics control efforts, the death penalty for some drug related crimes, and the admission of illegally obtained evidence in drug trials. In October 1986, Reagan signed the Anti-Drug Abuse Act. It supported much-harsher federal penalties than any other drug legislation in the United States ever passed, with mandatory minimum sentences for the distribution of cocaine and far more severe punishments for the distribution of crack. It outlined a 100-1 discrepancy in prison terms for crack versus powder cocaine. An individual caught with 5 g of crack cocaine would face a five-year sentence. An individual would need to be caught with 500 g of powder cocaine to carry the same sentence. Many scholars have argued that these laws were racist in nature since crack was a drug identified by the media and the public to be associated with black America and powder cocaine with white America. In addition, scholars have pointed out that data from states like New York, where mandatory minimum sentencing had originated a decade earlier, show that mandatory minimums lead to a disproportionate number of arrests of black Americans. The Act was revisited by the administration in 1988 to allow public housing authorities to evict a tenant who allowed drug-related activity to occur on or near public housing premises.
== Early life == Peña was born on 16 November 1978 in Asunción, Paraguay to José María Peña Nieto (a Paraguayan) and Ana María Palacios (an Argentine from Buenos Aires). He has two brothers: Manuel and Francisco Peña. Through his father's side he is a direct descendant of former dictator José Gaspar Rodríguez de Francia, considered to be Paraguay's founding father.
=== Mood disorders === In the case of mood disorders, specifically bipolar disorder, it is hypothesized that N-acetyl-cysteine (NAC), acetyl-L-carnitine (ALCAR), S-adenosylmethionine (SAMe), coenzyme Q10 (CoQ10), alpha-lipoic acid (ALA), creatine monohydrate (CM), and melatonin could be potential treatment options.
The separation is the inverse of the maximum OPD. For example, a maximum OPD of 2 cm results in a separation of 0.5 cm−1. This is the spectral resolution in the sense that the value at one point is independent of the values at adjacent points. Most instruments can be operated at different resolutions by choosing different OPD's. Instruments for routine analyses typically have a best resolution of around 0.5 cm−1, while spectrometers have been built with resolutions as high as 0.001 cm−1, corresponding to a maximum OPD of 10 m. The point in the interferogram corresponding to zero path difference has to be identified, commonly by assuming it is where the maximum signal occurs. This so-called centerburst is not always symmetrical in real world spectrometers so a phase correction may have to be calculated. The interferogram signal decays as the path difference increases, the rate of decay being inversely related to the width of features in the spectrum. If the OPD is not large enough to allow the interferogram signal to decay to a negligible level there will be unwanted oscillations or sidelobes associated with the features in the resulting spectrum. To reduce these sidelobes the interferogram is usually multiplied by a function that approaches zero at the maximum OPD. This so-called apodization reduces the amplitude of any sidelobes and also the noise level at the expense of some reduction in resolution. For rapid calculation the number of points in the interferogram has to equal a power of two. A string of zeroes may be added to the measured interferogram to achieve this.
Sources: en.wikipedia.org
=== British Isles === A half and half is commonly understood to be a side dish of half chips and half rice. The term is used across the British Isles but most commonly in the north of England and Wales. A typical order might be "chicken curry half and half" or "chili con carne half and half".
Deep gas-phase reactor oxidation of ethylene oxide at 800–1,000 K (527–727 °C; 980–1,340 °F) and a pressure of 0.1–1 MPa (15–145 psi) yields a complex mixture of products containing O2, H2, CO, CO2, CH4, C2H2, C2H4, C2H6, C3H6, C3H8, and CH3CHO.
== Agriculture == In the farming industry, environmental concerns over air pollution led to research aimed at reducing the odor of manure. A body of evidence emerged that increased sulfur containing amino acid content of feed increased the offensive odor of feces and flatus produced by livestock. This is thought to be due to increased sulfur containing substrate available to gut microbiota enabling increased volatile sulfur compound (VSC) release during gut fermentation (VSC are thought to be the primary contributors to the odor of flatus and feces). This theory is supported by the observation that feces from carnivores is more malodorous than feces from herbivore species, and this appears to apply to human diets as well (odor of human feces shown to increase with increased dietary protein, particularly sulfur containing amino acids).
Narrow face is a dysmorphic feature in which its width is abnormally reduced (upper and lower face width less than 2 SD below the mean subjectively, or apparent reduction of the width of the upper and lower face objectively).
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
Purity is commonly estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection. Mass spectrometry is used to confirm identity and to detect sequence-related impurities. Reported percentages depend on the method and the impurity threshold used.